Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference
01 mars 2021 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
25 févr. 2021 02h00 HE
|
Verona Pharma plc
Positive Phase 2 results with pMDI ensifentrine in COPD Enrollment ongoing in ENHANCE Phase 3 program Up to $30 million debt finance facility increases financial flexibility Conference...
Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
18 févr. 2021 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD
02 févr. 2021 06h17 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Verona Pharma plc (Nasdaq: VRNA), please note that all instances of the unit...
Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD
02 févr. 2021 02h00 HE
|
Verona Pharma plc
Primary and secondary lung function endpoints met Results support twice-daily dosing LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”),...
Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19
14 janv. 2021 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
05 janv. 2021 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma Secures up to $30 Million Debt Financing from Silicon Valley Bank
23 nov. 2020 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma Announces November 2020 Virtual Investor Conference Participation
09 nov. 2020 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020
29 oct. 2020 03h00 HE
|
Verona Pharma plc
Initiated ENHANCE Phase 3 clinical trials in COPD Completed $200 million private placement Commenced a pilot clinical study in U.S. patients hospitalized with COVID-19 ...